PALO ALTO, Calif. / Aug 15, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on July 22, 2025, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 239,565 shares of its common stock to 189 new non-executive employees and two non-qualified stock option awards to purchase 23,542... Read More

Together, American Cancer Society and Guardant Health aim to remove barriers and increase cancer screening rates in communities that have historically limited access to preventive cancer care. SAN FRANCISCO / Aug 04, 2025 / Business Wire / The American Cancer Society (ACS) today announced a new partnership with Guardant Health (Nasdaq: GH), a leading precision oncology company focused on improving access to cancer screening... Read More

PALO ALTO, Calif. / Jul 31, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming Canaccord Genuity 45 th Annual Growth Conference in Boston, MA. Guardant Health’s management is scheduled to participate in a fireside chat on Wednesday, August 13 th at 9:30 a.m. ET. Interested parties may access live and archived webcasts... Read More

Revenue growth of 31% broadly driven by strong performance across Oncology, Screening, and Biopharma & Data Raises 2025 revenue guidance to $915 to $925 million, representing growth of 24% to 25% PALO ALTO, Calif. / Jul 30, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended June 30, 2025. Second Quarter 2025 Financial... Read More

75% of patients who die from colorectal cancer (CRC) are not screened, often because traditional options are viewed as unpleasant or inconvenient Guardant’s FDA-approved Shield offers screening with a simple blood draw from any prescribing healthcare provider for adults 45+ at average risk for CRC After a CRC diagnosis, Van Der Beek is speaking up for the first time to advocate to get more people screened PALO ALTO, Calif. /... Read More

The first readout from Guardant’s research collaboration with the Parker Institute for Cancer Immunotherapy (PICI) shows Guardant Reveal detected responses to immunotherapy across multiple tumor types and identified non-responders up to 5 months earlier than standard methods Study shows Guardant Reveal’s promise for confirming effective therapies earlier and optimizing treatment faster in patients with advanced cancer PALO... Read More

Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participants Shield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) PALO ALTO, Calif. / Jul 15, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s... Read More

PALO ALTO, Calif. / Jul 14, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2025 after market close on Wednesday, July 30, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the... Read More

PALO ALTO, Calif. / Jun 10, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named a winner of Fast Company’s 2025 World Changing Ideas Awards. These annual awards recognize innovative companies and projects addressing the world’s most urgent challenges. Shield is the first blood test approved... Read More

LIBERATE Study: Guardant Reveal showed high sensitivity and 100% positive predictive value for relapse PALO ALTO, Calif. / Jun 09, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced results from the LIBERATE study published in ESMO Open . The results in the peer-reviewed manuscript demonstrate the clinical validity and high performance of Guardant Reveal, the... Read More

PALO ALTO, Calif. / Jun 03, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that its Shield multi-cancer detection (MCD) test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA). The Shield MCD test is a methylation-based blood test for the multi-cancer screening of multiple cancer types including bladder,... Read More

First national guideline recommendation for Shield paves the way for improved patient access and additional major guideline inclusions NCCN guidelines point to landmark ECLIPSE Study showing efficacy of Shield Shield is FDA-approved for adults age 45 or older at average risk for colorectal cancer PALO ALTO, Calif. / Jun 02, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today... Read More

First pivotal trial to use a circulating tumor DNA (ctDNA)-guided approach to detect and treat emerging resistance in 1st-line therapy ahead of disease progression in breast cancer Trial showed AstraZeneca’s camizestrant reduced risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation as detected by Guardant360 CDx PALO ALTO, Calif. / Jun 02, 2025 /... Read More

Data support routine use of circulating tumor DNA testing in management of stage III colon cancer patients Tumor fraction analysis provides further insights for patient management in patients with ctDNA detected PALO ALTO, Calif. / May 31, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and its research collaborators today presented results of the largest study to date... Read More

For the first time, fundamental tumor phenotypes determined by a simple blood test Single test now provides molecular tumor typing, subtyping and confirmation of absence of actionable biomarkers to give clinicians critical insights to guide optimal treatment PALO ALTO, Calif. / May 27, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced major new features for the... Read More

Plenary session to highlight use of Guardant360 CDx test in detecting emerging ESR1 mutations during first line endocrine therapy in advanced breast cancer in Phase 3 SERENA-6 trial Oral session to feature largest study evaluating tissue-free epigenomic-based molecular residual disease (MRD) detection in colon cancer using Guardant Reveal PALO ALTO, Calif. / May 22, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH),... Read More

Complete suite of IHC testing for key biomarkers in all solid tumors, including c-MET, now available in addition to Guardant360 Tissue multiomic profiling test PALO ALTO, Calif. / May 21, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the addition of a full suite of immunohistochemistry (IHC) testing to the company’s portfolio of tumor molecular profiling... Read More

New Guardant Hereditary Cancer test offers germline testing to identify guideline-recommended genetic variants associated with cancer risk across 12+ tumor types Results help guide treatment decisions and enable healthcare providers to assess patient risk for secondary cancers PALO ALTO, Calif. / May 20, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the... Read More

PALO ALTO, Calif. / May 08, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. BofA Securities 2025 Healthcare Conference in Las Vegas, NV Fireside chat on Wednesday, May 14 th at 3:40 p.m. Pacific Time Jefferies Global Healthcare Conference in New York, NY Fireside chat on Wednesday, June 4... Read More

PALO ALTO, Calif. / May 08, 2025 / Business Wire / Today TIME named to its 2025 TIME100 Health list co-CEOs Helmy Eltoukhy and AmirAli Talasaz of Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company. The list recognizes and honors the top 100 most influential people in global health this year. “The inclusion on TIME100 Health’s list is more than a personal honor,” said AmirAli Talasaz, Guardant Health... Read More

PALO ALTO, Calif. / May 07, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 22, 2025, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 157,466 shares of its common stock to 139 new non-executive employees and two non-qualified stock option awards to purchase 19,295... Read More

Revenue growth of 21% broadly driven by strong performance across oncology, screening, and biopharma & data Raises 2025 revenue guidance to $880 to $890 million, representing growth of 19% to 20% PALO ALTO, Calif. / Apr 30, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial... Read More

Blood-based Shield Multi-Cancer Detection (MCD) test exhibits high specificity, clinically meaningful sensitivity and strong cancer signal of origin accuracy Results informed National Cancer Institute's selection of Shield MCD test for highly anticipated Vanguard Study PALO ALTO, Calif. / Apr 29, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, presented data today from a study... Read More

Powered by Guardant Infinity smart liquid biopsy platform, advanced multiomic test evaluates genomic, epigenomic and RNA-based molecular data First tissue comprehensive genomic profiling test to offer genome-wide tumor methylation analysis Advanced molecular profiling test requires 40% fewer tissue slides than industry norm, allowing researchers and oncologists to test more patients with less precious tissue PALO ALTO,... Read More

Powered by Guardant Infinity smart liquid biopsy platform, advanced multiomic test evaluates genomic, epigenomic and RNA-based molecular data First tissue comprehensive genomic profiling test to offer exome-wide tumor methylation analysis Advanced molecular profiling test requires 40% fewer tissue slides than industry norm, allowing researchers and oncologists to test more patients with less precious tissue PALO ALTO, Calif.... Read More

Multi-year global collaboration will utilize Guardant liquid biopsy portfolio in research and clinical applications and evaluate utility of ctDNA for monitoring therapy response PALO ALTO, Calif. / Apr 24, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a strategic collaboration with Pfizer, Inc. (NYSE: PFE), to support the development and commercialization of... Read More

Four oral sessions to be presented, including validation data for Shield MCD test, selected for highly anticipated NCI Vanguard Study 18 total abstracts to showcase significant developments in multiomic profiling with liquid and tissue biopsies across screening, recurrence monitoring and treatment selection PALO ALTO, Calif. / Apr 22, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology... Read More

PALO ALTO, Calif. / Apr 10, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2025 after market close on Wednesday, April 30, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the... Read More

Guardant tests for cancer screening, recurrence monitoring and treatment selection will be available to patients through Bayshore HealthCare providers PALO ALTO, Calif. / Apr 03, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has entered into an agreement with Bayshore HealthCare, a leading home and community healthcare service provider in Canada, to offer... Read More

US veterans and eligible family members now have access to blood test for colorectal cancer screening with no copay Benefit will cover all eligible individuals ages 45-84, representing first coverage beyond Medicare population for Shield PALO ALTO, Calif. / Mar 25, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer... Read More

Approval demonstrates unique value of Shield test for CRC screening and improves Medicare pricing PALO ALTO, Calif. / Mar 11, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Centers for Medicare & Medicaid Services (CMS) has approved Advanced Diagnostic Laboratory Test (ADLT) status for the Shield™ blood test for colorectal cancer (CRC) screening. The U.S.... Read More

Foundation’s grant to mobile cancer screening program in Louisiana allows individuals to be screened with Guardant’s Shield™ blood test in their own community Mobile screening events to be held during Colorectal Cancer Awareness Month (March) throughout northern and central Louisiana PALO ALTO, Calif. / Mar 05, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a... Read More

PALO ALTO, Calif. / Feb 28, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 11, 2025, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 110,681 shares of its common stock to 102 new non-executive employees and one non-qualified stock option award to purchase 22,091... Read More

93% of primary care providers believe patients are less likely to avoid screening if presented with an FDA-approved blood test option March is Colorectal Cancer Awareness Month Shield is first blood test approved by FDA as a primary screening option for CRC PALO ALTO, Calif. / Feb 27, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of the second... Read More

Full year 2024 total revenue growth of 31% driven by strong clinical oncology volume growth, Guardant360 ASP tailwinds, and product upgrades Expects full year 2025 total revenue to be in the range of $850 to $860 million PALO ALTO, Calif. / Feb 20, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31,... Read More

PALO ALTO, Calif. / Feb 10, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. BTIG 12 th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT Hosting 1x1 meetings on Tuesday, February 11 th and Wednesday, February 12 th TD Cowen 45 th Annual Health Care... Read More

PALO ALTO, Calif. / Feb 07, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 6, 2025, it entered into privately negotiated exchange agreements (the “Exchange Agreements”) with certain holders of its outstanding 0% Convertible Senior Notes due 2027 (the “2027 Notes”), pursuant to which the Company will issue $600 million aggregate principal... Read More

PALO ALTO, Calif. / Jan 30, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2024 after market close on Thursday, February 20, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be... Read More

Health officials introduce blood test as a more pleasant option to encourage greater participation in screening and boost early detection of colorectal cancer PALO ALTO, Calif. / Jan 30, 2025 / Business Wire / Guardant Health, Inc . (Nasdaq: GH), a leading precision oncology company, today announced an agreement with the Abu Dhabi Public Health Center (ADPHC) to introduce a non-invasive blood-based screening program for... Read More

Data shared from phase II NEO trial highlights Guardant Reveal™ as a decision tool to support organ preservation in rectal cancer PALO ALTO, Calif. / Jan 23, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data showcasing the benefits of Guardant’s precision oncology tools across cancer screening,... Read More

Blood test for minimal residual disease (MRD) now covered to monitor for disease recurrence after curative intent treatment Tissue-free approach addresses need for cancer patients who have no tissue available or for whom tissue specimens are difficult to obtain PALO ALTO, Calif. / Jan 21, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Palmetto GBA, a... Read More

Collaboration enables insights from ConcertAI national database of 5.5M clinical records and Guardant profiling data across 60+ tumor types Longitudinal DNA methylation measurements and comprehensive genomic profiling allow deeper insights into intrinsic and acquired resistance mechanisms PALO ALTO, Calif., & CAMBRIDGE, Mass. / Jan 16, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology... Read More

Full year revenue growth of 31% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds PALO ALTO, Calif. / Jan 13, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended December 31, 2024. Fourth quarter 2024 preliminary unaudited financial results For the three-month period ended... Read More

Guardant Health Shield multi-cancer detection test selected on basis of strong performance in predicting presence of cancers and cancer tissue of origin Pilot study by National Cancer Institute’s Cancer Screening Research Network will inform design of future research evaluating use of multi-cancer detection blood tests to screen for cancer PALO ALTO, Calif.--( BUSINESS WIRE )-- Guardant Health, Inc. (Nasdaq: GH), a leading... Read More

PALO ALTO, Calif. / Jan 02, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming 43 rd Annual J.P. Morgan Healthcare Conference in San Francisco. Guardant Health’s management is scheduled to present and participate in a Q&A session on Monday, January 13, at 4:30 p.m. Pacific Time / 7:30 p.m. Eastern Time. Interested... Read More

PALO ALTO, Calif. & TAMPA, Fla. / Dec 20, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Meaningful Insights Biotech Analytics (MiBA), an innovative healthcare technology company, today announced a unique partnership aimed at optimizing the use of biomarker testing and data analytics to advance precision medicine in patient care throughout the MiBA Network. Recognizing... Read More

PALO ALTO, Calif. / Dec 18, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a collaboration with Boehringer Ingelheim to pursue the regulatory approval and commercialization of the Guardant360 ® CDx liquid biopsy as a companion diagnostic (CDx) for zongertinib, an investigational covalent tyrosine kinase inhibitor (TKI) that selectively inhibits HER2 while... Read More

Spotlight presentation using Guardant Reveal™ test suggests ctDNA has potential to predict sensitivity to endocrine therapy and long-term outcomes in HR+ breast cancer PALO ALTO, Calif. / Dec 09, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data demonstrating the benefits of its precision oncology... Read More

Guardant Health Secures One of the Largest False Advertising Verdicts in History, Representing a Significant Victory for Colorectal Cancer Patients Who Could Benefit from Guardant Reveal™ Natera Found to Have Willfully Misled Oncologists in an Effort to Thwart Competition PALO ALTO, Calif. , Nov. 25, 2024 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH) ("Guardant Health"), a leading precision oncology company, today... Read More

PALO ALTO, Calif. / Nov 13, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on October 22, 2024, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 233,603 shares of its common stock to 123 new non-executive employees and non-qualified stock option awards to purchase an... Read More

Revenue growth of 34% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds Shield received favorable Medicare pricing of $920 PALO ALTO, Calif. / Nov 06, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights Recorded revenue of $191.5 million for... Read More

PALO ALTO, Calif. / Nov 01, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences. ● Guggenheim Inaugural Healthcare Innovation Conference in Boston, MA Fireside chat on Tuesday, November 12 at 10:30 a.m. Eastern Time ● Wolfe Healthcare Conference in New York, NY Hosting 1x1 meetings on Tuesday,... Read More

Shield™, the first FDA-approved, Medicare-reimbursed colorectal cancer screening blood test, named to the Medical Care list PALO ALTO, Calif. / Oct 30, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the inclusion of its blood-based colorectal cancer screening product Shield in TIME’s annual list of the Best Inventions, which features 200 extraordinary... Read More

Less than half of patients who underwent stool-based CRC screening completed recommended repeat testing PALO ALTO, Calif. / Oct 28, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data supporting the critical role of blood-based testing in increasing overall colorectal cancer (CRC) screening adherence at... Read More

PALO ALTO, Calif. / Oct 24, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a pioneer in precision oncology, today announced the appointment of Roberto A. Mignone to its board of directors, effective immediately. Mr. Mignone is the Founder and Managing Partner of Bridger Management LLC, an investment management firm founded in 2000 and specializing in long-term equity strategies. “We are fortunate to welcome... Read More

PALO ALTO, Calif. / Oct 15, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, November 6, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the... Read More

In study of more than 4,000 patients with advanced gastrointestinal tumors, 24% were able to receive targeted treatment based on genomic profiling results from blood test Study findings are expected to advance liquid biopsy-guided cancer treatment to help improve outcomes for more patients PALO ALTO, Calif. / Sep 18, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today... Read More

PALO ALTO, Calif. / Sep 13, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from several studies utilizing Guardant technology to advance precision oncology at the European Society for Medical Oncology Congress (ESMO) in Barcelona, Spain, Sept. 13-17, 2024. Data on the Guardant Reveal™ minimal... Read More

Leading Italian Hospital System To Offer Proprietary Guardant360 ® CDx Liquid Biopsy Testing for Therapy Selection in Advanced Cancer Patients PALO ALTO, Calif. / Sep 10, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a partnership with the Agostino Gemelli University Polyclinic Foundation IRCCS (“Policlinico Gemelli”) to establish an in-house liquid biopsy... Read More

PALO ALTO, Calif. / Aug 27, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming Morgan Stanley 22 nd Annual Global Healthcare Conference in New York, NY. Guardant Health’s management is scheduled to participate in a fireside chat on Thursday, September 5 th at 11:30 a.m. ET. Interested parties may access live and... Read More

PALO ALTO, Calif. / Aug 22, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will ring the opening bell at the Nasdaq MarketSite in Times Square, New York on Wednesday, August 28, 2024. “We recently launched Shield, our FDA-approved blood-based screening test, marking a pivotal moment on our journey to conquer cancer with data. We are thrilled to... Read More

PALO ALTO, Calif. / Aug 08, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences. Canaccord Genuity 44 th Annual Growth Conference in Boston, MA Fireside chat on Tuesday, August 13 at 10:30 a.m. ET UBS Genomic Medicine Summit in Dana Point, CA Panel discussion: Future of Cancer Screening on... Read More

Revenue growth of 29% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds Shield approved by FDA as primary option for CRC screening and is commercially available in U.S. PALO ALTO, Calif. / Aug 07, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended June 30, 2024. Second Quarter 2024 Financial... Read More

Largest study to date evaluating MRD detection using tissue-free approach demonstrates 81% longitudinal sensitivity for recurrence in stage II or higher colon cancer Data demonstrate potential clinical utility of ctDNA as tool to improve management of stage II and higher CRC that allows for rapid evaluation without complexity of prior tissue analysis PALO ALTO, Calif. / Aug 07, 2024 / Business Wire / Guardant Health, Inc.... Read More

FDA approval announced earlier this week makes Shield first blood test that is approved for primary screening of colorectal cancer and meets coverage requirements for Medicare reimbursement Commercial launch of Shield and CMS coverage make blood-based screening option more accessible to millions of individuals at average risk for the disease PALO ALTO, Calif. / Aug 01, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq:... Read More

Research Study Accepted for Publication Demonstrates Efficacy of Blood-Based Tests for CRC Screening PALO ALTO, Calif. / Aug 01, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the acceptance of its health outcomes study, the CAN-SCREEN model, for publication in the Journal of Medical Economics , highlighting the importance of combining clinically meaningful... Read More

Shield is first blood test approved by FDA as a primary screening option for colorectal cancer and that meets performance requirements for Medicare coverage Blood test offers easy, convenient and pleasant screening option with potential for improving colorectal cancer screening rates Guardant Health to host investor conference... Read More

PALO ALTO, Calif. / Jul 24, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the... Read More

Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered by Medicare and major private payers for comprehensive genomic profiling of all advanced solid tumors PALO ALTO, Calif. / Jul 23, 2024 / Business... Read More

PALO ALTO, Calif. / Jul 18, 2024 / Business Wire / Guardant Health, Inc. (NASDAQ:GH), a pioneer in precision oncology, today announced the appointment of Dr. Manuel Hidalgo Medina to its board of directors, effective immediately. Dr. Hidalgo currently serves as Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center. “Dr. Hidalgo brings a wealth... Read More

Upgraded gene panel on tissue genomic profiling test covers 498 biomarkers, including guideline-recommended genes Operational improvements streamline workflow and shorten time to results Upgraded test covered by Medicare for comprehensive genomic profiling of all advanced solid tumors PALO ALTO, Calif. / Jun 04, 2024 / Business Wire / Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced... Read More

Data from study using Guardant360® blood test show Black patients with PIK3CA mutations in advanced breast cancer were less likely than White patients to be enrolled in clinical trials and receive targeted therapy Study is part of collaboration between Guardant Health and Multicenter Precision Medicine Academic Consortium (PMAC) using liquid biopsy to achieve equitable use of precision medicine therapies in patients with... Read More

Guardant’s Impact, Innovation, Ambition, and Success Contributed to the Recognition PALO ALTO, Calif. / May 31, 2024 / Business Wire / Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced its inclusion in the fourth-annual TIME100 Most Influential Companies list, highlighting companies making an extraordinary impact around the world. TIME solicited nominations across sectors, and polled... Read More

Studies demonstrate benefits of liquid biopsy and real-world data in targeted therapy selection and therapeutic outcomes in advanced breast cancer Interim data from PICI’s RADIOHEAD study using Guardant Infinity™ platform show correlation between epigenomic biomarkers and patient response to immunotherapy treatment across more than 13 cancer types PALO ALTO, Calif. / May 30, 2024 / Business Wire / Guardant Health, Inc.... Read More

The advisory committee offers valuable non-binding recommendations for the FDA Blood test offers a convenient non-invasive screening option that overcomes barriers associated with current non-invasive screening tests Shield remains on track to become the first FDA-approved blood test that meets performance requirements for Medicare coverage 1 PALO ALTO, Calif. / May 23, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq:... Read More

PALO ALTO, Calif. / May 23, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Nasdaq has temporarily halted trading of the company's stock. The Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration (FDA) Medical Devices Advisory Committee will meet today to review the premarket approval (PMA) application for Shield TM , Guardant... Read More

PALO ALTO, Calif. / May 22, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences. William Blair 44 th Annual Growth Stock Conference in Chicago Presentation on Tuesday, June 4 at 3:20 p.m. CT / 4:20 p.m. ET Jefferies Global Healthcare Conference in New York Presentation on Wednesday, June 5 at 5:00... Read More

Blood-based test for comprehensive genomic profiling of solid cancers meets requirements under stricter EU In Vitro Diagnostic Regulation IVDR certification from TÜV SÜD enables broader adoption of guideline-recommended genomic profiling to inform optimal therapy selection for patients with advanced cancer PALO ALTO, Calif. / May 21, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology... Read More

PALO ALTO, Calif. / May 17, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 22, 2024, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 215,601 shares of its common stock to 94 new non-executive employees and non-qualified stock option awards to purchase an aggregate... Read More

PALO ALTO, Calif. / May 16, 2024 / Business Wire / Guardant Health, Inc . (Nasdaq: GH), a leading precision oncology company, today announced it will present data from two real-world studies at the 2024 Digestive Disease Week (DDW) meeting in Washington, DC, highlighting the value of the company’s Shield™ test in colorectal cancer (CRC) screening. “One in three eligible American adults have not been screened for CRC, in part... Read More

Revenue growth of 31% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds PALO ALTO, Calif. / May 09, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2024. First Quarter 2024 Financial Highlights Revenue of $168.5 million for the first quarter of 2024, an increase of 31% over the first... Read More

PALO ALTO, Calif. / May 07, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences. BofA Securities 2024 Healthcare Conference in Las Vegas Fireside Chat on Wednesday, May 15 at 10:40 a.m. PT / 1:40 p.m. ET Leerink Partners 2024 Healthcare Crossroads Conference in Austin, Texas Fireside Chat on... Read More

PALO ALTO, Calif. / May 07, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its achievement of surpassing a significant milestone of 500 peer-reviewed publications featuring its technology in esteemed scientific journals. This milestone highlights Guardant Health’s leadership, amassing one of the most robust portfolios of relevant liquid biopsy research studies... Read More

PALO ALTO, Calif. / Apr 22, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration Medical Devices Advisory Committee is scheduled to review the premarket approval (PMA) application for the company’s Shield™ blood test for colorectal cancer (CRC) screening on Thursday, May 23, 2024. “We... Read More

PALO ALTO, Calif. / Apr 18, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2024 after market close on Thursday, May 9, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the... Read More

New research demonstrates value of epigenomic analysis and methylation sequencing with Guardant liquid biopsy portfolio across continuum of cancer care New data show strong performance of Guardant Reveal™ in detection and quantification of residual disease in early-stage breast cancer without need for tissue specimen PALO ALTO, Calif. / Apr 03, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision... Read More

Study shows blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% Results pave the way for first potential FDA-approved blood test for colorectal cancer screening to meet requirements for Medicare coverage PALO ALTO, Calif. / Mar 13, 2024 / Business Wire / Guardant Health, Inc.... Read More

PALO ALTO, Calif. / Mar 06, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 15, 2024, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 218,236 shares of its common stock to 82 new non-executive employees and non-qualified stock option awards to purchase an... Read More

Findings from the first ‘Closing the Gap: CRC Screening Insights’ survey, released during National Colorectal Cancer Awareness Month, suggest more convenient blood-based testing could transform colorectal cancer screening by encouraging the 50 million Americans behind in screening to stay up to date PALO ALTO, Calif. / Mar 01, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company,... Read More

Full year 2023 revenue growth of 25% driven by clinical volume growth of 39% Expects full year 2024 revenue to be in the range of $655 to $670 million PALO ALTO, Calif. / Feb 22, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights Revenue of $155.1... Read More

PALO ALTO, Calif. / Feb 15, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences. Citi 2024 Unplugged Medtech and Life Sciences Access Day in New York Fireside Chat on Thursday, February 29 at 1:00 p.m. Eastern Time / 10:00 a.m. Pacific Time TD Cowen 44 th Annual Health Care Conference in Boston... Read More

PALO ALTO, Calif. / Feb 01, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2023 after market close on Thursday, February 22, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be... Read More

COSMOS study shows Guardant Reveal™ blood test highly predictive for disease recurrence in patients with early-stage colon cancer without need for tissue specimen PALO ALTO, Calif. / Jan 17, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present interim data from the COSMOS study supporting the use of Guardant Reveal to predict disease recurrence in patients with... Read More

Full year revenue growth of 25% driven by clinical volume growth of 39% PALO ALTO, Calif. / Jan 08, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended December 31, 2023. Full year 2023 preliminary unaudited financial results For the twelve-month period ended December 31, 2023, as compared to the... Read More

PALO ALTO, Calif. / Jan 08, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Hikma Pharmaceuticals PLC (“Hikma”), a multinational pharmaceutical company, today announced an agreement to promote Guardant Health’s portfolio of liquid and tissue biopsy tests for cancer screening, recurrence monitoring and tumor mutation profiling across all solid cancers in countries across... Read More

PALO ALTO, Calif. / Jan 02, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the addition of Terilyn Juarez Monroe as the company’s chief people officer, effective immediately. In the newly-created role, Monroe will lead the human resources function, including people operations; cultural and organizational transformation; talent acquisition; and diversity and... Read More

PALO ALTO, Calif. / Dec 21, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that it has entered into a common stock purchase agreement with Baillie Gifford on behalf of accounts that it manages for the sale of 3,387,446 shares of its common stock in a registered direct offering at an offering price of $26.77 per share. Gross proceeds are approximately $90.7... Read More

PALO ALTO, Calif. / Dec 20, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming 42 nd Annual J.P. Morgan Healthcare Conference in San Francisco. Guardant Health’s management is scheduled to present and participate in a Q&A session on Monday, January 8, at 3:45 p.m. Pacific Time / 6:45 p.m. Eastern Time. Interested... Read More

PALO ALTO, Calif. / Dec 19, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is tentatively scheduled to review the premarket approval application (PMA) for the company’s Shield™ blood test to screen for colorectal cancer on March 28,... Read More

Mission-focused collaboration to explore opportunities to help accelerate the discovery and development of cancer drugs and diagnostics for patients LONDON & PALO ALTO, Calif. / Dec 04, 2023 / Business Wire / Cancer Research UK, one of the world’s largest charitable funders of cancer research, its innovation unit, Cancer Research Horizons, and Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today... Read More

Spotlight sessions highlight role of Guardant blood tests in tissue-free detection of minimal residual disease and predictive impact of ctDNA genomic profiling MRD study found ctDNA detection after adjuvant therapy using Guardant Reveal™ was prognostic for distant recurrence of cancer nearly eight months before detected via standard of care surveillance PALO ALTO, Calif. / Nov 30, 2023 / Business Wire / Guardant Health, Inc.... Read More

PALO ALTO, Calif. / Nov 15, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on November 8, 2023, the Compensation Committee of Guardant’s Board of Directors granted restricted stock units (“RSUs”) representing 50,741 shares of its common stock to 43 new non-executive employees under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan... Read More

PALO ALTO, Calif. / Nov 15, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it intends to appeal yesterday’s verdict in the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington. “We strongly disagree with this decision and will vigorously... Read More

SINGAPORE , Nov. 12, 2023 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that it has launched its blood-based colorectal cancer screening test, Shield TM , in collaboration with Samsung Medical Center in South Korea . Colorectal cancer (CRC) is one of the most commonly diagnosed cancers and the third-leading cause of cancer-related deaths in South Korea . 1,2 Guardant... Read More

Q3 revenue increased 22% year over year driven by clinical volume growth of 35% Raises 2023 revenue guidance to $553 to 556 million PALO ALTO, Calif. / Nov 06, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter... Read More

PALO ALTO, Calif. / Nov 03, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences: Jefferies 14 th Annual Global Healthcare Conference in London, UK Presentation on Thursday, November 16 at 9:00 a.m. Greenwich Mean Time Piper Sandler 35 th Annual Healthcare Conference in New York, NY Fireside Chat on... Read More

Seamless ordering and receipt of genomic test results directly in patient records streamlines clinician access to precision medicine tools PALO ALTO, Calif. & CAMBRIDGE, Mass. / Oct 31, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Flatiron Health , a leading healthtech company dedicated to expanding the possibilities of point of care solutions in oncology and closing... Read More

Study results suggest Guardant Reveal TM circulating tumor DNA blood test may help clinicians decide to pursue more or less aggressive post-surgical chemotherapy regimens PEGASUS is first clinical utility trial for tissue-free detection of minimal residual disease PALO ALTO, Calif. / Oct 23, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that initial results... Read More

First blood-only liquid biopsy test for minimal residual disease now covered for patients with stage II or III colorectal cancer Test used after surgery or curative treatment to inform physician decisions about adjuvant therapy and to monitor for disease progression, recurrence or relapse PALO ALTO, Calif. / Sep 06, 2023 / Business Wire / Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, announced... Read More

Blood test provides simple way for oncologists to test patients with advanced NSCLC for genomic alterations that drive selection of HER2-targeted therapy PALO ALTO, Calif. / Sep 05, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the Guardant360® CDx liquid biopsy test as a companion... Read More

PALO ALTO, Calif. / Sep 01, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today issued the following statement about the closure of COBRA, a minimum residual disease (MRD) study. The COBRA study was designed to evaluate the effectiveness of using MRD testing to improve clinical outcomes in patients with stage II colon cancer after curative-intent surgery with a planned final... Read More

PALO ALTO, Calif. / Aug 31, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming Morgan Stanley 21 st Annual Global Healthcare Conference in New York, New York. Guardant Health’s management is scheduled to participate in a fireside chat on Monday, September 11, at 11:20 a.m. Eastern Time / 8:20 a.m. Pacific Time.... Read More

PALO ALTO, Calif. / Aug 17, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today announced the company will be hosting an Investor Day on September 7, 2023, in New York City, NY starting at 8:00 a.m. Eastern time / 5:00 a.m. Pacific Time. The event will... Read More

Q2 revenue increased 26% year over year driven by clinical volume growth of 49% Raises 2023 revenue guidance to $545 to $550 million PALO ALTO, Calif. / Aug 03, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter... Read More

PALO ALTO, Calif. / Aug 01, 2023 / Business Wire / Guardant Health, Inc. (NASDAQ: GH), a leading precision oncology company, today announced an agreement with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, that resolves their pending litigation and promotes a shared resolution to advance the companies’ long-term, commercial partnership. The three-year agreement includes a joint... Read More

First blood-only liquid biopsy test for molecular residual disease now covered for serial testing in patients with stage II or III colorectal cancer Test used after surgery or curative treatment to inform physician decisions about adjuvant therapy and to monitor for disease progression, recurrence or relapse PALO ALTO, Calif. / Jul 20, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology... Read More

PALO ALTO, Calif. / Jul 12, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will report financial results for the second quarter of 2023 after market close on Thursday, August 3, 2023. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be... Read More

Reimbursement supports expanded access to blood-based comprehensive genomic profiling with Guardant360 CDx for patients with advanced solid tumor cancers and their care teams across Japan PALO ALTO, Calif. / Jul 05, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it has been informed it will receive national reimbursement approval from the Japanese... Read More

New research further confirms value of interrogating epigenomic signals with Guardant Infinity™ platform to identify novel biomarker targets and predict treatment resistance PALO ALTO, Calif. / May 31, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that the company and its research collaborators will present data from 17 studies that highlight the contribution... Read More

Guardant360 ® CDx is a comprehensive genomic profiling blood test that provides critical information to help inform personalized treatment decisions for patients with advanced solid cancers The liquid biopsy test is also approved as a companion diagnostic for TAGRISSO ® (osimertinib) in non-small cell lung cancer This is the first blood test to be approved by Singapore's Health Sciences Authority for comprehensive genomic... Read More

PALO ALTO, Calif. / May 26, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. William Blair 43 rd Annual Growth Stock Conference in Chicago, IL Presentation on Tuesday, June 6 th at 4:40 p.m. Central Time Goldman Sachs 44 th Annual Global Healthcare Conference in Dana Point, CA Fireside Chat... Read More

PALO ALTO, Calif. / May 22, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq:GH), a leading precision oncology company, today announced the pricing of an upsized underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $28.00 per share, before deducting underwriting discounts and commissions. In addition, Guardant Health has granted the underwriters a 30-day option to purchase... Read More

PALO ALTO, Calif. / May 22, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq:GH), a leading precision oncology company, today announced that it has commenced an underwritten public offering of $250.0 million of its common stock. In addition, Guardant Health intends to grant the underwriters a 30-day option to purchase up to $37.5 million of its common stock at the public offering price, less underwriting discounts and... Read More

With new coverage from Anthem Blue Cross and Blue Shield, Aetna and Humana, Guardant360 CDx/Guardant360 liquid biopsy test now covered by all major commercial health insurers Only blood test approved by FDA as companion diagnostic for ORSERDU™ (elacestrant), Guardant360 CDx gains coverage by Aetna and Humana to identify eligible patients with advanced breast cancer prior to initiation of treatment PALO ALTO, Calif. / May 17,... Read More

PALO ALTO, Calif. / May 16, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the publication of its inaugural Environmental, Social & Governance (ESG) Report, which provides information related to key ESG commitments that the company has laid out as part of its business strategy. “Our goal from day one has been to provide tests for patients at all stages of... Read More

Q1 revenue increased 34% year over year driven by clinical volume growth of 45% Raises 2023 revenue guidance to $535 to $545 million PALO ALTO, Calif. / May 09, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter... Read More

Shield™ blood test achieved overall 83% sensitivity and 90% specificity and demonstrated early-stage detection in range with other guideline-recommended non-invasive CRC screening modalities PALO ALTO, Calif. / May 09, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today presented additional data from the ECLIPSE study at 2023 Digestive Disease Week (DDW) titled, “Clinical... Read More

Ines Dahne-Steuber named as chief operating officer Darya Chudova promoted to chief technology officer PALO ALTO, Calif. / May 08, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the expansion of its leadership team with the addition of Ines Dahne-Steuber as chief operating officer and the promotion of Darya Chudova to chief technology officer. “At Guardant, we... Read More

PALO ALTO, Calif. / May 05, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report additional data from its pivotal ECLIPSE study at Digestive Disease Week (DDW) on Tuesday, May 9, 2023. The company will host a webcast and conference call with primary investigators of the study and other cancer screening experts beginning at 11:00 a.m. ET / 8:00 a.m.... Read More

PALO ALTO, Calif. / Apr 27, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming BofA Securities 2023 Healthcare Conference in Las Vegas, Nevada. Guardant Health’s management is scheduled to present a fireside chat on Wednesday, May 10 th at 2:20 p.m. Pacific Time / 5:20 p.m. Eastern Time. Interested parties may... Read More

Project will identify genomic and epigenomic biomarkers in patient blood samples from PICI’s RADIOHEAD study using GuardantINFINITY™ Goal of mission-focused collaboration is to help accelerate development and utilization of immune therapies for cancer PALO ALTO, Calif., & SAN FRANCISCO / Apr 25, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and the Parker Institute for... Read More

The data from the pivotal ECLIPSE Study accepted as a late-breaking abstract highlights the performance of the Shield™ blood test in detecting colorectal cancer in asymptomatic patients PALO ALTO, Calif. / Apr 21, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, is pleased to announce that it will present data from two studies highlighting the performance of its blood-based... Read More

PALO ALTO, Calif. / Apr 19, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter of 2023 after market close on Tuesday, May 9, 2023. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on... Read More

First blood-only liquid biopsy test for monitoring molecular response to immune checkpoint inhibitors now covered for US Medicare patients with metastatic or inoperable solid tumors PALO ALTO, Calif. / Apr 18, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostics Services program... Read More

New research demonstrates value of epigenomic analysis and methylation sequencing capabilities of GuardantINFINITY™ platform for biomarker discovery, therapy selection and response monitoring PALO ALTO, Calif. / Apr 11, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it will present data from 14 studies highlighting advances in precision oncology and... Read More

PALO ALTO, Calif. / Mar 21, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has announced support for an investigator initiated study led and conducted by The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute ( OSUCCC – James ) to evaluate patient compliance with a blood-based test for colorectal cancer... Read More

PALO ALTO, Calif. / Mar 10, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that it has submitted to the U.S. Food and Drug Administration (FDA) the final module of its premarket approval (PMA) application for Shield ™ , Guardant Health’s blood test to screen for colorectal cancer (CRC). The submission is comprised of data from the company’s positive ECLIPSE... Read More

PALO ALTO, Calif. / Feb 27, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the appointment of Musa Tariq to its board of directors, effective March 6. Currently the chief marketing officer for GoFundMe, the world’s leading fundraising platform, Tariq is a distinguished marketing executive with experience leading global consumer brands. “We are very pleased to... Read More

PALO ALTO, Calif. / Feb 15, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced the initiation of a new study to examine patient preference for Shield, Guardant Health’s blood test to screen for colorectal cancer (CRC), and if having the option of a blood test improves patient adherence to screening. The study will be conducted by the Center for Asian Health Equity –... Read More

PALO ALTO, Calif. / Feb 08, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that UnitedHealthcare (UHC) now covers the Guardant360® CDx liquid biopsy test for patients enrolled in its commercial policies for all FDA-approved companion diagnostic indications. The test is used by oncologists as a companion diagnostic to assess if patients are eligible for a... Read More

Collaboration is Guardant Health’s first to explore both tissue- and blood-based assays as companion diagnostics (CDx) PALO ALTO, Calif. & NEW YORK / Feb 02, 2023 / Business Wire / Guardant Health Inc. (Nasdaq: GH), a leading precision oncology company, and AnHeart Therapeutics, a clinical-stage global biopharmaceutical company committed to developing novel precision oncology therapeutics, announced today a strategic... Read More

Nearly all of Illumina’s claims to be dismissed as filed PALO ALTO, Calif / Feb 02, 2023 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, issued the following statement today regarding the favorable recommendation by U.S. District Court Magistrate Judge Christopher J. Burke that nearly all claims brought by Illumina against Guardant Health in a lawsuit filed on March 17, 2022, be... Read More

Suite of AI-powered expert systems and discovery platforms will be developed internally and through outside partnerships First application using AI-backed image analysis developed by Lunit® for Guardant360 TissueNext TM PD-L1 test improves biomarker detection by >20% in NSCLC Future planned applications include deep learning-driven genomic, epigenomic and spatial biomarker discovery via collaboration with biopharma partners... Read More

ESR1 mutations, a known driver of resistance to standard endocrine therapy, are present in up to 40% of ER+, HER2- advanced breast cancers 1 ORSERDU (elacestrant) is first FDA-approved endocrine therapy innovation in more than 20 years, specifically addressing ESR1 mutations, a major unmet need Guardant360 CDx blood test provides comprehensive genomic profiling to identify patients with ESR1 mutations who may benefit from... Read More

Trial will evaluate use of circulating tumor DNA to guide chemotherapy treatment decisions following surgery for stage II-III colorectal cancer patients based on test results for minimal residual disease with Guardant Reveal™ blood test Study involving approximately 40 sites and 1600+ patients across the United Kingdom aims to evaluate opportunity to improve patient care and quality of life by reducing unnecessary use of... Read More

Presentations to highlight role of Guardant liquid biopsy tests and real-world data to help identify actionable biomarkers and predict disease recurrence and response to therapy Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that new data from its portfolio of blood tests will be presented at the ASCO 2023 Gastrointestinal Cancers Symposium, January 19-21 in San Francisco. The 10... Read More

Full year clinical and biopharma volumes up 42% and 40% year over year Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today announced preliminary, unaudited results for the year ended December 31, 2022. Full year 2022 preliminary unaudited financial results For the twelve-month... Read More

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming 41 st Annual J.P. Morgan Healthcare Conference. Guardant Health’s management is scheduled to present and participate in a Q&A session on Monday, January 9 th at 3:00 p.m. Pacific Time / 6:00 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation... Read More

Collaboration will help researchers understand value of monitoring breast cancer patients for residual or recurring disease with Guardant Reveal™ blood test Susan G. Komen Advocates in Science will provide patient perspective to inform design of research studies and strategies for personalized cancer care Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Susan G. Komen®, the world’s leading breast... Read More